




# What Clinicians Need to Know About Available Therapeutic Options for COVID-19

## Overview

Medications are available that can reduce chances of severe illness and death from COVID-19 infection. Oral antivirals are available that can reduce chances of severe illness and death from COVID-19 infection. The Food & Drug Administration issued emergency use authorizations for certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get sick. The National Institutes of Health also provides COVID-19 treatment guidelines for healthcare providers for treating COVID-19 at home or in an outpatient setting. During this COCA Call, subject matter experts will present an overview of COVID-19 therapeutic options, including indications, efficacy, and distribution.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the [COCA Call webpage](#) a few hours after the live event ends.

The slide set will be available on the day of the call on the [COCA Call webpage](#) under Call Materials.



**Date:** Thursday, June 16, 2022

**Time:** 2:00 PM – 3:00 PM ET

**A few minutes before the webinar starts, please click on the Zoom link below to join:**  
<https://www.zoomgov.com/j/1603960029?pwd=Z0x1SE1mR3ZNUXFSK3hBckw3aFlyUT09>

**Passcode:** 308026

**Or Telephone:**

US: +1 669 254 5252 or  
+1 646 828 7666 or  
+1 551 285 1373 or  
+1 669 216 1590

**Or One-tap mobile:**

US: +16692545252,,1603960029#,,,,\*308026#  
or +16468287666,,1603960029#,,,,\*308026#

[Free Continuing Education \(CE\)](#) will be offered for this COCA Call.

Registration is not required.

**Webinar ID:** 160 396 0029

**International numbers available:**  
<https://www.zoomgov.com/join/ab2qcyEiu7>

## Activity-specific Objectives

At the conclusion of the session, the participant will be able to accomplish the following—

1. Describe key points about COVID-19 rebound after use of Paxlovid.
2. Describe Paxlovid use, prescribing, and availability.
3. Discuss where to find more information about COVID-19 therapeutics and availability.

## COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following—

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC's role in the topic covered during the presentation.
3. Describe the topic's implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

## Presenters

### **Dan Filardo, MD**

Epidemic Intelligence Service Officer  
Core Clinical Unit  
Epidemiology Task Force  
COVID-19 Response  
Centers for Disease Control and Prevention

### **Eric Daar, MD**

Chief, Division of HIV Medicine  
Harbor-UCLA Medical Center  
Clinical Guidelines Team  
National Institutes of Health

## Instructions for Obtaining Continuing Education

To receive continuing education (CE) for **WC4520-061622** – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – **What Clinicians Need to Know About Available Therapeutic Options for COVID-19, Thursday, June 16, 2022**, please visit [TCEO](#) and follow these [9 Simple Steps](#) by **Monday, July 18, 2022**.

To receive continuing education (CE) for **WD4520-061622** – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – **What Clinicians Need to Know About Available Therapeutic Options for COVID-19, Thursday, June 16, 2022**, (Web on Demand), please visit [TCEO](#) and follow these [9 Simple Steps](#) between **Tuesday, July 19, 2022, and Friday, July 19, 2024**.

## Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**CME:** The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**AAPA CME:** The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation.

**CNE:** The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

**CPE:** The Centers for Disease Control and Prevention designated this **(Knowledge-based)** event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is **JA4008229-0000-22-057-L04-P** and enduring **JA4008229-0000-22-058-H04-P**.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

**CEU:** The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

**CECH:** Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to **1.0** total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are **1**. Continuing Competency credits available are **1**. CDC provider number **98614**.

**AAVSB/RACE:** This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at [race@aavsb.org](mailto:race@aavsb.org) if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.

**For Certified Public Health Professionals (CPH):** The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer **1** CPH recertification credits for this program.

**DISCLOSURE:** In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, with the exception of Dr. Eric Daar who would like to disclose that he provides research support and is a consultant related to HIV for Gilead, Merck, and GSK/ViiV.

All of the relevant financial relationships listed for this individual has been mitigated.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

---

**The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.**

For information about this update or other clinical issues, or to send your feedback, please contact us at [coca@cdc.gov](mailto:coca@cdc.gov)

- [CDC Clinician Outreach and Communication Activity Facebook page](#)—connect with COCA on Facebook

- [Clinician Outreach and Communication Activity](#)—resources for healthcare providers
- [COCA RSS Feed](#)—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
- [Crisis & Emergency Risk Communication Training](#)—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
- [Health Alert Network](#)—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories



CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.



## Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

[Questions or Problems](#) | [Unsubscribe](#)